Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
暂无分享,去创建一个
N. Marascio | C. Torti | M. Mazzitelli | E. Trecarichi | F. Serapide | G. Greco | V. Pisani | C. Costa | V. Scaglione | R. Lionello | V. La Gamba | Rosaria Lionello | Vincenzo Scaglione
[1] R. Sterling,et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores. , 2019, Gastroenterology.
[2] M. Pistello,et al. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases. , 2019, The new microbiologica.
[3] M. Monami,et al. Direct‐acting antivirals for HCV treatment in older patients: A systematic review and meta‐analysis , 2019, Journal of viral hepatitis.
[4] Todd A. Lee,et al. Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist–Driven Model , 2019, Open forum infectious diseases.
[5] I. Gentile,et al. Efficacy of the "first wave" Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort. , 2019, The new microbiologica.
[6] C. Indolfi,et al. Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients , 2018, BMC Infectious Diseases.
[7] G. Giannelli,et al. Liver Angiopoietin‐2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting Antivirals , 2018, Hepatology.
[8] K. Childs,et al. Efficacy and Tolerability of Direct‐Acting Antivirals for Hepatitis C in Older Adults , 2018, Journal of the American Geriatrics Society.
[9] E. Asante-Appiah,et al. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial , 2018, Hepatology.
[10] B. Bacon,et al. Real‐world use of elbasvir‐grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network , 2018, Alimentary pharmacology & therapeutics.
[11] G. Coppolino,et al. Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals , 2018, Clinical and molecular hepatology.
[12] M. Massari,et al. Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study , 2018, PloS one.
[13] R. Stauber,et al. Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus , 2017, Wiener Klinische Wochenschrift.
[14] A. Shlomai,et al. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[15] T. Asselah,et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension , 2017, Journal of viral hepatitis.
[16] B. Bacon,et al. Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients , 2017, Alimentary pharmacology & therapeutics.
[17] P. Pafundi,et al. Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C , 2017, Journal of clinical pharmacology.
[18] M. Massari,et al. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study , 2017, PloS one.
[19] B. Bacon,et al. Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study , 2017, Journal of viral hepatitis.
[20] S. Zeuzem,et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection , 2016, Alimentary pharmacology & therapeutics.
[21] N. Terrault,et al. Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[22] A. Walker,et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.
[23] D. Samuel,et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. , 2015, Gastroenterology.
[24] M. Manns,et al. Extrahepatic morbidity and mortality of chronic hepatitis C. , 2015, Gastroenterology.
[25] G. Foti,et al. Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) , 2012, BMC Infectious Diseases.
[26] S. Pol,et al. FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.
[27] M. Campbell,et al. Noninvasive Assessment of Liver Fibrosis by Measurement of Stiffness in Patients With Chronic Hepatitis C , 2006 .